Frieder Fuchs
Impact in
-
- Antibiotic Use and Resistance
- Infectious Diseases top 5%
- Antifungal resistance and susceptibility
- COVID-19 Clinical Research Studies
- Antimicrobial Resistance in Staphylococcus
Papers in
-
- Antifungal resistance and susceptibility 7
- Epidemiology 10
- Urinary Tract Infections Management 4
- Mycobacterium research and diagnosis 3
- Fungal Infections and Studies 2
- Co-authors
- Axel Hamprecht (10 shared papers)Oliver A. Cornely (5 shared papers)Philipp Koehler (4 shared papers)Jan Rybniker (3 shared papers)Michael Hallek (1 shared paper)Florian Klein (1 shared paper)Thorsten Persigehl (1 shared paper)Norma Jung (1 shared paper)
- Journals
- Mycoses (4 papers)Clinical Microbiology and Infection (4 papers)Journal of Antimicrobial Chemotherapy (2 papers)Microbiology Spectrum (2 papers)Antimicrobial Agents and Chemotherapy (2 papers)
- Partner nations
- GermanyUnited StatesSpain
In The Last Decade
Frieder Fuchs
29 papers receiving 689 citations
Peers
Comparison fields: 5 of 67
- Applied Microbiology and Biotechnology 50
- Infectious Diseases 406
- Molecular Medicine 80
- Endocrinology 57
- Critical Care and Intensive Care Medicine 43
Countries citing papers authored by Frieder Fuchs
This map shows the geographic impact of Frieder Fuchs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frieder Fuchs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frieder Fuchs more than expected).
Fields of papers citing papers by Frieder Fuchs
This network shows the impact of papers produced by Frieder Fuchs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frieder Fuchs. The network helps show where Frieder Fuchs may publish in the future.
Co-authors
The 25 scholars most cited alongside Frieder Fuchs, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 405 | |
| 2 | 2021 | 32 | |
| 3 | 2021 | 29 | |
| 4 | 2019 | 23 | |
| 5 | 2019 | 21 | |
| 6 | 2021 | 18 | |
| 7 | 2022 | 16 | |
| 8 | 2019 | 16 | |
| 9 | 2022 | 15 | |
| 10 | 2023 | 13 | |
| 11 | 2019 | 12 | |
| 12 | 2022 | 11 | |
| 13 | 2023 | 10 | |
| 14 | 2023 | 9 | |
| 15 | 2022 | 9 | |
| 16 | 2024 | 8 | |
| 17 | 2022 | 7 | |
| 18 | 2022 | 7 | |
| 19 | 2023 | 7 | |
| 20 | 2023 | 6 |
About Frieder Fuchs
Frieder Fuchs is a scholar working on Infectious Diseases, Epidemiology, Molecular Medicine, Endocrinology and Molecular Biology, having authored 33 papers that have together received 699 indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (10 papers), Antifungal resistance and susceptibility (7 papers), Urinary Tract Infections Management (4 papers), Mycobacterium research and diagnosis (3 papers), Fungal Infections and Studies (2 papers), Heme Oxygenase-1 and Carbon Monoxide (2 papers), Legionella and Acanthamoeba research (2 papers) and Phenothiazines and Benzothiazines Synthesis and Activities (2 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (50 citations), Infectious Diseases (406 citations), Molecular Medicine (80 citations), Endocrinology (57 citations) and Critical Care and Intensive Care Medicine (43 citations). Frieder Fuchs has collaborated with scholars based in Germany, United States and Spain. Frequent co-authors include Axel Hamprecht, Oliver A. Cornely, Philipp Koehler, Jan Rybniker, Michael Hallek, Florian Klein, Thorsten Persigehl, Norma Jung, Boris Böll and Dennis A. Eichenauer. Their work appears in journals such as Mycoses, Clinical Microbiology and Infection, Journal of Antimicrobial Chemotherapy, Microbiology Spectrum and Antimicrobial Agents and Chemotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.